Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULFINPYRAZONE vs PROBALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.
Inhibits xanthine oxidase, reducing uric acid production.
Chronic gouty arthritis,Hyperuricemia,Off-label: Prevention of gout flares during initiation of allopurinol
Gout,Hyperuricemia,Prevention of tumor lysis syndrome
100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.
500 mg orally once daily.
2-5 hours (terminal elimination half-life; prolonged in renal impairment to up to 10 hours)
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (Cr Cl <30 m L/min) requiring dose adjustment.
Primarily hepatic via oxidation and conjugation; major metabolite is sulfinpyrazone sulfide.
Primarily hepatic via CYP450; produces active metabolites.
Renal: ~90% (50% unchanged, 50% as glucuronide and other metabolites); Biliary/fecal: ~10%
Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for 15-25% with the remainder as metabolites.
98-99% (primarily to albumin)
90-95% bound primarily to albumin and alpha-1-acid glycoprotein.
0.15-0.25 L/kg (low Vd, consistent with high protein binding and limited tissue distribution)
0.15-0.25 L/kg; reflects distribution mainly into extracellular fluid with limited tissue penetration.
Oral: 80-90% (well absorbed; decreased with food)
Oral: 75-85% (first-pass metabolism reduces absolute bioavailability); Intravenous: 100%.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Cr Cl 30-50 m L/min: 250 mg daily; Cr Cl <30 m L/min: 125 mg daily; hemodialysis: 125 mg after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: not recommended.
Safety and efficacy not established; use not recommended.
10 mg/kg orally once daily, max 500 mg; for children <2 years: 5 mg/kg once daily.
Start at lower end of dosing range (100-200 mg daily) and titrate cautiously due to increased risk of renal impairment and drug interactions.
Start at 250 mg daily; monitor renal function and adjust based on Cr Cl.
None.
None
Risk of acute gouty attacks during initial therapy,Uricosuric effect may lead to urolithiasis; maintain adequate hydration and urine alkalinization,Possible cross-allergenicity with sulfonamides,Monitor renal function and complete blood counts
Acute gout flares may occur initially,Hypersensitivity reactions including Stevens-Johnson syndrome,Renal impairment requires dose adjustment
Active peptic ulcer disease,Known hypersensitivity to sulfinpyrazone or sulfonamides,Severe hepatic or renal impairment
Hypersensitivity to probalan,Concurrent use with azathioprine or mercaptopurine
Avoid high-purine foods (e.g., organ meats, anchovies, sardines, beer) as they may reduce efficacy. Maintain adequate hydration; alcohol consumption should be minimized as it can increase uric acid levels.
High-purine foods (organ meats, anchovies, sardines) may increase uric acid; limit intake. Alcohol, especially beer, reduces uricosuric effect and increases uric acid; avoid or limit. Aspirin (anti-inflammatory doses) and some diuretics (thiazides) can reduce efficacy; avoid concurrent use.
Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of congenital malformations. Second and third trimester use may cause adverse fetal effects including premature closure of the ductus arteriosus, oligohydramnios, and renal dysfunction.
PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with third-trimester exposure due to inhibition of fetal renal clearance. Risk cannot be excluded; use only if maternal benefit outweighs potential fetal risk.
Sulfinpyrazone is excreted into breast milk in small amounts. The M/P ratio is unknown. Due to the risk of serious adverse reactions in nursing infants, including the potential for kernicterus in jaundiced infants, use during breastfeeding is not recommended.
Probenecid is excreted into breast milk in small amounts. M/P ratio is approximately 0.1. Infant exposure is negligible, but caution is advised due to potential for kernicterus in jaundiced infants. Consider discontinuing breastfeeding if infant is G6PD deficient.
No specific dose adjustments have been established. Due to increased renal blood flow and glomerular filtration rate during pregnancy, pharmacokinetics may be altered, but no dose recommendations are available. Sulfinpyrazone is not recommended for use in pregnancy.
No standard dose adjustment recommended. Pregnancy increases renal clearance and volume of distribution, potentially reducing serum concentrations. Consider therapeutic drug monitoring if response inadequate. Avoid use in third trimester unless benefits outweigh risks.
Sulfinpyrazone is a uricosuric agent used for chronic gout; avoid in acute gout attack. Monitor renal function and uric acid levels. Contraindicated in peptic ulcer disease due to GI irritation. May potentiate warfarin and sulfonylureas; adjust doses accordingly.
PROBALAN (probenecid) is a uricosuric agent used for chronic gout. Monitor serum uric acid levels; goal <6 mg/d L. Avoid in patients with creatinine clearance <50 m L/min or history of uric acid stones. Ensure adequate hydration (≥2 L/day) to prevent nephrolithiasis. Alkalinize urine (p H 6.5-7.0) with potassium citrate if needed. Contraindicated with aspirin >1 g/day due to decreased uricosuric effect. Not effective during acute gout attacks; initiate after inflammation subsides.
Take with food or milk to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce effectiveness.,Report any signs of bleeding, bruising, or abdominal pain immediately.,Do not stop abruptly; discuss with your doctor.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2 liters of water daily to prevent kidney stones.,Avoid aspirin or aspirin-containing products; use acetaminophen for pain.,Report rash, fever, or painful urination immediately.,May take several months to achieve full effect; do not stop suddenly.
"Tolvaptan, a vasopressin V2 receptor antagonist, may increase the serum concentration of sulfinpyrazone, a uricosuric agent, primarily through inhibition of OATP1B1/1B3 and possibly other hepatic uptake transporters. This interaction can lead to elevated sulfinpyrazone levels, raising the risk of adverse effects such as renal impairment or hypersensitivity reactions. Careful monitoring and dose adjustment of sulfinpyrazone are recommended when coadministered with tolvaptan."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, is a substrate of P-glycoprotein (P-gp) and may induce P-gp expression. Sulfinpyrazone, a uricosuric agent and P-gp inhibitor, can increase the bioavailability and systemic exposure of rifaximin by inhibiting its efflux transport. This interaction may lead to elevated rifaximin serum concentrations, potentially increasing the risk of systemic adverse effects such as Clostridioides difficile infection or hepatic impairment, though clinical data on this specific combination are limited."
"Colchicine may increase the serum concentration of sulfinpyrazone, a uricosuric agent, potentially enhancing its therapeutic effect and risk of toxicity. This interaction is likely mediated by colchicine's inhibition of hepatic cytochrome P450 enzymes and/or interference with biliary excretion of sulfinpyrazone. Clinically, this could lead to elevated sulfinpyrazone levels, increasing the risk of adverse effects such as gastrointestinal disturbances, hypersensitivity reactions, or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULFINPYRAZONE vs PROBALAN, answered by our medical review team.
SULFINPYRAZONE is a Uricosuric that works by Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.. PROBALAN is a Uricosuric Agent that works by Inhibits xanthine oxidase, reducing uric acid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULFINPYRAZONE and PROBALAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULFINPYRAZONE is: 100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.. The standard adult dose of PROBALAN is: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULFINPYRAZONE and PROBALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULFINPYRAZONE is classified as Category A/B. Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of. PROBALAN is classified as Category C. PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.